Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Company Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Key Stats

• Today's Range: $2.35 to $2.55
• 50-Day Range: $2.08 to $3.49
• 52-Week Range: $1.91 to $6.28
• Volume: 142,633 shs
• Average Volume: 454,641 shs
• Market Capitalization: $13.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.82
• Consensus Rating: Moderate Buy

Vivos Therapeutics Stock Analysis - MarketRank™

Vivos Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 626th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vivos Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivos Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivos Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivos Therapeutics has a P/B Ratio of 10.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.49% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 20.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivos Therapeutics does not currently pay a dividend.

Dividend Growth

Vivos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.49% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 20.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.58

News Sentiment

Vivos Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vivos Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Vivos Therapeutics is held by insiders.

Percentage Held by Institutions

Only 26.35% of the stock of Vivos Therapeutics is held by institutions.

VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed this year?

Vivos Therapeutics' stock was trading at $4.29 at the beginning of 2025. Since then, VVOS stock has decreased by 45.0% and is now trading at $2.36.
View the best growth stocks for 2025 here.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Thursday, May, 15th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The business earned $3.70 million during the quarter, compared to the consensus estimate of $3.63 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 335.04% and a negative net margin of 86.19%.
Read the conference call transcript.

When did Vivos Therapeutics' stock split?

Shares of Vivos Therapeutics reverse split on the morning of Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Who are Vivos Therapeutics' major shareholders?

Top institutional investors of Vivos Therapeutics include Cutter & CO Brokerage Inc. (0.83%) and EWA LLC (0.18%).
View institutional ownership trends.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vivos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VVOS
• CIK: 1716166
• Web: www.vivoslife.com
• Phone: 866-908-4867
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.82
• High Stock Price Target: $6.20
• Low Stock Price Target: $2.25
• Potential Upside/Downside: +101.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.58 million
• Net Margins: -86.19%
• Pretax Margin: -86.19%
• Return on Equity: -335.04%
• Return on Assets: -93.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $14.63 million
• Price / Sales: 0.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 10.86

Miscellaneous

• Outstanding Shares: 5,890,000
• Free Float: 5,713,000
• Market Cap: $14.08 million
• Optionable: Optionable
• Beta: 7.31